drugset / Trial / NCT04714827
Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma
Phase 1/2
Unknown
24 enrolled
Shanxi Province Cancer Hospital
Novatim Immune Therapeutics (Zhejiang) Co., Ltd. · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
Evaluation the safety,tolerability, preliminary efficacy,and PK/PD of KQ-2003 CAR-T cells for the treatment of multiple myeloma
Timeline
- Start
- 2021-01-22
- Primary completion
- 2024-09-30
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KQ-2003 | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | KQ-2003 | Cell therapy | 2.5e+06 cells/kg | Intravenous |
| Subject | KQ-2003 | Cell therapy | 5e+06 cells/kg | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 300 mg/m2 | — |
| Background | Fluorine dara marina | Unknown | 30 mg/m2 | — |